Neogenomics (NEO) Cash from Investing Activities (2010 - 2026)

Neogenomics (NEO) has reported Cash from Investing Activities for 17 consecutive years, with -$5.0 million the latest figure, recorded in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$5.0 million, down 240.45% year-over-year; the trailing twelve-month figure through Mar 2026 was -$20.9 million (down 1205.61% YoY), and the FY2025 annual result was -$12.3 million, down 195.96% from the prior year.
• Cash from Investing Activities was -$5.0 million for Q1 2026 at Neogenomics, up from -$6.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $23.7 million in Q1 2023 and troughed at -$9.3 million in Q2 2025.
• Average Cash from Investing Activities over 5 years is $4.3 million, with a median of -$277000.0 recorded in 2025.
• Year-over-year, Cash from Investing Activities jumped 1717.59% in 2023 and slumped 240.45% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$1.1 million in 2022, then surged by 1717.59% to $17.2 million in 2023, then tumbled by 131.79% to -$5.5 million in 2024, then declined by 15.33% to -$6.3 million in 2025, then advanced by 20.7% to -$5.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$5.0 million in Q1 2026, -$6.3 million in Q4 2025, and -$277000.0 in Q3 2025.